

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.clinicaltrialsarena.com/news/fda-nls-narcolepsy-phase-iii/
https://www.accesswire.com/737215/NLS-Pharmaceutics-Announces-Completion-of-Open-Label-Extension-Study-with-Quilience-Mazindol-ER-for-the-Treatment-of-Narcolepsy
https://www.accesswire.com/736677/NLS-Pharmaceutics-Regains-Compliance-with-Nasdaq-Stockholders-Equity-Requirement
https://www.accesswire.com/736231/NLS-Pharmaceutics-Announces-New-In-Vitro-Data-Reconfirming-QuiliencesR-Mazindol-ER-Unique-Dual-Mechanism-of-Action-Involving-Significant-Orexin-2-Receptor-Activity
https://www.accesswire.com/732543/NLS-Pharmaceutics-Announces-Israeli-Patent-Grant-Covering-Mazindol-for-Treatment-of-Attention-Deficit-Hyperactivity-Disorder-and-Other-Sleep-Disorders-Through-2037